MedTrace Logo

Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population

NCT00450905 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2008-10-06

No results posted yet for this study

Summary

This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.

Conditions

Interventions

DEVICE

PRIMA Device

Sponsors & Collaborators

  • PharmaNet

    collaborator INDUSTRY

  • McDougall Scientific Limited

    collaborator UNKNOWN

  • Fralex Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Completion
2008-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00450905 on ClinicalTrials.gov